ePulmonology Review

Revised PH Classifications and New Treatment Developments

In this issue:

The updated (2022) ESC/ERS (European Society of Cardiology/European Respiratory Society) guidelines provide new definitions of pulmonary hypertension (PH) with lowered diagnostic thresholds, as well as revised treatment algorithms based on risk stratification at diagnosis and follow-up. Findings from the multicenter INCREASE study of inhaled treprostinil, and the phase 3 STELLAR trial of sotatercept, provide new evidence for the use of these agents in particular patients with PH. How actionable are the data supporting these changes? How is implementing them expected to improve patient outcomes? And all in all, what do these developments mean to the practicing pulmonologist?

These are some of the questions addressed by Catherine Simpson MD, MHS, and Darin Rosen, MD, from the Division of Pulmonary and Critical Care at Johns Hopkins School of Medicine, in this issue of ePulmonology Review.

Learning objectives:

• Explain how the revised 2022 ESC/ERS guidelines, including the lowered thresholds indicating PH, may change clinical practice.
• Describe the current research regarding the expanded indication for inhaled treprostinil for individuals with PH associated with interstitial lung disease.
• Discuss the current clinical trial evidence in support of sotatercept, a novel fusion protein that alters TGF-beta signaling, as a potential new therapy for PAH.